Trials / Withdrawn
WithdrawnNCT06886009
Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis
A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Spesolimab in Korean Patients With Flares With Generalized Pustular Psoriasis
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The primary and secondary objectives are to respectively monitor the safety and effectiveness of Spesolimab IV in Korean patients with flares with generalized pustular psoriasis (GPP) in a routine medical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Spevigo® | Intravenous |
Timeline
- Start date
- 2026-03-31
- Primary completion
- 2029-06-08
- Completion
- 2029-06-08
- First posted
- 2025-03-20
- Last updated
- 2026-03-31
Locations
4 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06886009. Inclusion in this directory is not an endorsement.